# Pharmaceuticals × Product & R&D Playbook

## Overview

Product & R&D in pharmaceutical companies is the engine of the entire business — responsible for discovering, developing, and bringing new drugs and therapies to market. This function typically represents 15-25% of total revenue spend and employs thousands of scientists, clinical researchers, regulatory affairs specialists, and program managers across global sites. The pipeline lifecycle — from target identification through preclinical, Phase I-III clinical trials, regulatory submission, and post-market surveillance — spans 10-15 years per compound with average costs exceeding $2.6 billion per approved drug.

The organizational structure is deeply matrixed. Therapeutic area (TA) teams (oncology, immunology, neuroscience, rare diseases) intersect with functional groups (medicinal chemistry, DMPK, toxicology, clinical operations, biostatistics, regulatory affairs, pharmacovigilance). Decision-making is governed by stage-gate processes, portfolio review committees, and extensive regulatory frameworks (FDA 21 CFR Part 11, EMA guidelines, ICH-GCP). Every workflow touches compliance — from electronic lab notebooks (ELNs) to clinical trial management systems (CTMS) to regulatory information management (RIM).

The current transformation pressure is enormous: patent cliffs on blockbuster biologics, the shift toward precision medicine and cell/gene therapies, and AI-driven drug discovery are forcing R&D organizations to radically rethink how they operate. Companies that can compress timelines, reduce attrition rates, and scale decision-making without proportional headcount growth will dominate the next decade.

## Value Driver Mapping

| Priority | Value Driver | Relevance | Why |
|----------|-------------|-----------|-----|
| 1 | Scale Impact Without Overhead | High | R&D headcount is expensive ($200-400K fully loaded per scientist). Scaling pipeline capacity without linear hiring is existential. |
| 2 | Consolidate Tech Stack with AI | High | Pharma R&D runs 50-100+ disconnected tools (ELN, LIMS, CTMS, eTMF, EDC, RIMS). Consolidation reduces validation burden and accelerates data flow. |
| 3 | Replace or Radically Augment Headcount | Medium-High | Regulatory writing, literature monitoring, and protocol amendment tracking consume thousands of FTE-hours that AI can absorb. |

## Prioritized Use Cases

---

### Use Case 1: Clinical Trial Portfolio Tracker & Stage-Gate Dashboard

**Relevance:** High
**Value Driver:** Scale Impact Without Overhead

#### The Pain
Portfolio review committees meet monthly to evaluate 30-80 active programs across phases. Data lives in separate CTMS (Medidata, Veeva Vault), project management tools, and spreadsheets. Program leads spend 15-20 hours per cycle assembling slide decks. Portfolio leaders lack real-time visibility into enrollment rates, site activation timelines, safety signals, and budget burn — making go/no-go decisions with stale data.

#### The Solution
monday.com Work Management as the portfolio command center. Each program is an item with structured columns: Therapeutic Area (dropdown), Phase (status: Discovery → Preclinical → Phase I → Phase II → Phase III → Filing → Approved), Indication (text), Lead Compound (text), Enrollment Target vs. Actual (numbers), First Patient In date (date), Primary Completion Date (date), Regulatory Submission Target (date), Program Lead (people), Budget Allocated vs. Spent (numbers), Risk Score (numbers), Go/No-Go Status (status). Dashboard views aggregate portfolio health by phase, TA, and risk. Timeline views show critical path dependencies. Automations notify stakeholders when milestones slip.

#### The Outcome
Eliminate 80% of manual portfolio reporting effort. Real-time stage-gate visibility reduces decision latency from weeks to hours. Portfolio committees can redirect $50-100M in investment toward higher-probability assets 2-3 months faster per cycle.

#### Discovery Questions
1. "How many active clinical programs are you tracking across phases right now, and how does your portfolio review committee get visibility into enrollment velocity and budget burn?"
2. "When a Phase II study misses its enrollment target by 20%, how quickly does that information reach the portfolio leadership — and what's the cost of delayed go/no-go decisions?"
3. "How many FTEs are dedicated to assembling portfolio review materials each cycle, and what percentage of that time is data aggregation vs. strategic analysis?"
4. "Are your stage-gate criteria standardized across therapeutic areas, or does each TA operate differently?"

#### Industry Context
Pharma portfolio management is fundamentally a capital allocation problem. Each program represents $50M-$500M+ in investment. Phase II-to-III transition decisions are the most consequential — attrition rates are ~70% in Phase II. The concept of "probability of technical and regulatory success" (PTRS) drives portfolio optimization. Understanding that SEs are speaking to people who think in terms of NPV, PTRS, and peak sales estimates is critical.

---

#### 🔧 VIBE PROMPT

> **"Build This Live" Prompt:**
>
> "Build a Clinical Trial Portfolio Tracker board with these columns: Program Name (text), Therapeutic Area (dropdown: Oncology, Immunology, Neuroscience, Rare Disease, Cardiovascular, Infectious Disease), Phase (status: Discovery, Preclinical, Phase I, Phase II, Phase III, Filing, Approved — with colors green for Approved, red for Discovery), Indication (text), Lead Compound ID (text), Program Lead (people), Enrollment Target (numbers), Enrollment Actual (numbers), First Patient In (date), Primary Completion Date (date), NDA/MAA Submission Target (date), Budget Allocated USD (numbers), Budget Spent USD (numbers), Risk Score (numbers 1-10), Go/No-Go Status (status: Go, Conditional Go, Hold, Terminate), Last Portfolio Review (date). Create groups by Therapeutic Area. Add a Timeline view showing all programs on a Gantt chart by phase dates. Add a Dashboard with: (1) chart showing program count by Phase as a stacked bar, (2) numbers widget for total portfolio budget, (3) chart showing enrollment actual vs target by program, (4) battery widget for average risk score. Add automations: when Go/No-Go Status changes to Hold, notify Program Lead and VP R&D; when Enrollment Actual < 50% of Enrollment Target and date is past First Patient In + 90 days, change Risk Score to 8 and notify Program Lead."

---

#### 🤖 AGENT BLUEPRINT — monday AI Agents *(coming soon)*

**Agent Name:** PipelineIQ
**Agent Purpose:** Continuously monitor clinical program health and proactively surface risks, delays, and portfolio optimization opportunities.

**Triggers:**
- Daily scheduled scan of all active programs at 7:00 AM EST
- When Enrollment Actual is updated on any program item
- When any program's Primary Completion Date is changed
- When Risk Score exceeds 7 on any item
- When a new safety signal note is added to an update

**Actions:**
- Compare enrollment velocity against historical Phase benchmarks and flag underperformers
- Generate weekly portfolio health summary with red/amber/green ratings per program
- When a program's timeline slips >30 days, automatically draft impact analysis on downstream programs
- Recommend portfolio rebalancing when budget utilization across TAs deviates >15% from plan
- Escalate to VP R&D when two or more Phase III programs simultaneously show enrollment shortfalls
- Auto-generate stage-gate presentation slides from current board data

**Data Required:**
- Integration with CTMS (Medidata Rave, Oracle Clinical) for enrollment data
- Budget actuals from ERP/finance systems
- Historical program attrition rates by phase and TA

**Autonomy Level:** Human-in-the-Loop
PipelineIQ generates analyses and recommendations autonomously but all go/no-go recommendations require human approval. Risk score adjustments above 8 require VP sign-off.

**Example Interaction:**
> PipelineIQ detects that the Phase III AURORA study in oncology has enrolled only 142 of 400 patients 6 months after First Patient In, putting it in the bottom quartile of historical enrollment velocity for solid tumor studies. The agent flags the program as "Enrollment Risk — Critical," updates the Risk Score to 9, and drafts an analysis: "At current velocity (23.7 pts/month), AURORA will miss its Primary Completion Date by approximately 8 months. Recommend evaluating: (1) adding 12-15 sites in Asia-Pacific where similar indications show 2.3x enrollment rates, (2) adjusting inclusion criteria per recent FDA guidance on biomarker-selected populations, (3) assessing portfolio impact on the NDA submission timeline for the combination therapy program dependent on AURORA data." The analysis is posted as an update on the program item and a notification is sent to the VP of Clinical Operations and the Portfolio Committee chair.

---

### Use Case 2: Regulatory Submission Tracker & Document Lifecycle

**Relevance:** High
**Value Driver:** Consolidate Tech Stack with AI

#### The Pain
Regulatory affairs teams manage hundreds of documents per submission — CTD modules, clinical study reports (CSRs), investigator brochures (IBs), CMC sections, labeling. These live across Veeva Vault RIM, SharePoint, email, and local drives. Tracking which documents are in draft, review, QC, or submission-ready across multiple health authorities (FDA, EMA, PMDA, NMPA) is a nightmare. Missed deadlines trigger Warning Letters or Refuse-to-File actions that can delay approval by 6-12 months, representing $500M+ in lost revenue for a blockbuster.

#### The Solution
monday.com as the regulatory submission command center. Each submission is a group. Items represent individual CTD sections/documents with columns: Module (dropdown: M1-M5), Document Type (dropdown: CSR, IB, CMC, Labeling, Nonclinical Summary), Health Authority (dropdown: FDA, EMA, PMDA, NMPA, Health Canada, TGA), Author (people), Reviewer (people), QC Owner (people), Status (status: Not Started → Drafting → Internal Review → QC → HA-Ready → Submitted), Target Submission Date (date), Actual Submission Date (date), Page Count (numbers), Version (numbers), Linked Study (connect boards). Automations enforce sequential review workflows. Dashboards show submission readiness by module and authority.

#### The Outcome
Reduce submission preparation time by 30-40%. Eliminate document version confusion that causes FDA Refuse-to-File letters. Give regulatory leadership a single view of multi-authority submission readiness, enabling parallel filings that capture $200-500M in first-mover revenue advantage.

#### Discovery Questions
1. "How many active regulatory submissions are you managing simultaneously across health authorities, and what's your current system for tracking document readiness across CTD modules?"
2. "Have you ever received a Refuse-to-File or validation error due to document version issues or missing components — and what was the revenue impact of that delay?"
3. "How do your regulatory affairs, clinical, and CMC teams coordinate on shared submission documents — is there a single source of truth for review status?"
4. "What's your average time from Last Patient Last Visit to NDA/MAA submission, and where are the biggest bottlenecks?"

#### Industry Context
The Common Technical Document (CTD) is the universal format for regulatory submissions (ICH M4). Module 1 is regional/administrative, Module 2 is summaries, Module 3 is CMC (Chemistry, Manufacturing, Controls), Module 4 is nonclinical, Module 5 is clinical. Submissions are electronic (eCTD format). The sequence of submission events — IND, Pre-NDA meeting, NDA/BLA filing, Advisory Committee, PDUFA date — is a well-defined cadence that SEs should reference confidently.

---

#### 🔧 VIBE PROMPT

> **"Build This Live" Prompt:**
>
> "Build a Regulatory Submission Tracker board. Groups: one per submission (e.g., 'NDA-2026-001 — DrugX Oncology'). Columns: CTD Module (dropdown: M1 Administrative, M2 Summaries, M3 Quality/CMC, M4 Nonclinical, M5 Clinical), Document Type (dropdown: Clinical Study Report, Investigator Brochure, CMC Dossier, Nonclinical Summary, Labeling, Cover Letter, Patent Certification), Health Authority (dropdown: FDA, EMA, PMDA, NMPA, Health Canada, TGA, MHRA), Author (people), Reviewer (people), QC Lead (people), Document Status (status: Not Started, Drafting, Internal Review, QC In Progress, QC Complete, HA-Ready, Submitted — colors: red for Not Started through green for Submitted), Target Date (date), Actual Submission Date (date), Version Number (numbers), Page Count (numbers), Priority (status: Critical Path, Standard, Low), Comments (text). Add a Kanban view grouped by Document Status. Add a Dashboard with: (1) chart of document count by Status per Module as stacked bar, (2) chart of documents by Health Authority, (3) timeline showing target dates for all critical path items, (4) numbers widget showing % HA-Ready. Add automations: when Document Status changes to Internal Review, notify Reviewer; when Document Status changes to QC Complete, notify Author and move to HA-Ready; when Target Date is within 7 days and Status is not QC Complete or later, notify Author, Reviewer, and QC Lead with 'URGENT: Submission document at risk'."

---

#### 🤖 AGENT BLUEPRINT — monday AI Agents *(coming soon)*

**Agent Name:** RegTrack
**Agent Purpose:** Monitor regulatory submission readiness, enforce document lifecycle compliance, and predict submission timeline risks.

**Triggers:**
- Daily scan at 6:00 AM for documents with Target Date within 14 days
- When Document Status changes on any item
- When a new document item is created
- Weekly scheduled comprehensive readiness assessment (Fridays at 3:00 PM)

**Actions:**
- Generate submission readiness scorecard (% complete by CTD module, by health authority)
- When a document enters Internal Review, check that all prerequisite documents in the same module are at QC Complete or later — if not, flag dependency risk
- Predict submission date feasibility based on historical velocity of similar document types through the review pipeline
- Auto-generate weekly regulatory status report for VP Regulatory Affairs
- When all M1-M5 documents for a health authority reach HA-Ready status, trigger "Submission Green Light" notification to Regulatory Head and General Counsel
- Flag when parallel authority submissions are drifting apart by >30 days (to maintain global launch alignment)

**Data Required:**
- Historical document review cycle times by type and module
- Health authority calendar (PDUFA dates, EMA validation timelines)
- Integration with Veeva Vault for document version sync

**Autonomy Level:** Escalation-Based
Status tracking and readiness scoring are fully autonomous. Timeline risk predictions are shared as recommendations. Any action that could affect a submission timeline requires human approval.

**Example Interaction:**
> RegTrack identifies that the NDA-2026-001 submission has 47 of 52 documents at HA-Ready for FDA, but Module 3 (CMC) has 3 documents still in QC — specifically the Drug Substance Specification (DSS), the Container Closure System report, and the Stability Summary. The agent calculates that based on historical QC cycle times for CMC documents (average 8.2 days), the earliest all three can reach HA-Ready is February 28, which is 4 days past the internal target of February 24. RegTrack posts: "⚠️ NDA-2026-001 FDA Filing Risk: Module 3 CMC has 3 documents in QC. Projected HA-Ready: Feb 28 (4 days past target). Recommend: (1) Prioritize DSS — it's the dependency for Stability Summary, (2) Request expedited QC from CMC QC Lead, (3) Pre-submission meeting with FDA is March 15 — current trajectory still allows filing but eliminates buffer." It notifies the VP Regulatory Affairs and the CMC Quality Lead.

---

### Use Case 3: Preclinical Study Tracker & IND-Enabling Package

**Relevance:** High
**Value Driver:** Scale Impact Without Overhead

#### The Pain
Before a drug candidate enters human trials, 15-30 preclinical studies must be completed — toxicology (single-dose, repeat-dose, carcinogenicity), pharmacokinetics/ADME, safety pharmacology, genotoxicity, reproductive toxicity. These studies are conducted across internal labs and 3-5 CROs (Contract Research Organizations), each with different timelines, protocols, and reporting formats. Tracking study status, protocol deviations, GLP compliance, and data readiness for the IND (Investigational New Drug) application is managed through spreadsheets and email. A single missed study can delay IND filing by 6-12 months.

#### The Solution
monday.com board per IND-enabling package. Items represent individual studies with columns: Study Type (dropdown: Single-Dose Tox, Repeat-Dose Tox, Carcinogenicity, Safety Pharm — CV, Safety Pharm — Respiratory, Safety Pharm — CNS, Genotox — Ames, Genotox — Micronucleus, ADME, PK, Reproductive Tox), Species (dropdown: Rat, Mouse, Dog, NHP, Rabbit), CRO/Lab (dropdown), Study Director (people), GLP Status (status: GLP, Non-GLP), Protocol Status (status: Draft, Approved, Amended), In-Life Start (date), In-Life End (date), Report Draft (date), Report Final (date), Study Status (status: Planning → In-Life → Pathology → Draft Report → Final Report → QA Reviewed), Deviations (numbers), IND Section (dropdown: Pharm/Tox, CMC, Clinical). Timeline view shows critical path to IND filing.

#### The Outcome
Reduce IND preparation cycle by 2-3 months through better CRO coordination and early identification of study delays. Eliminate the "last study syndrome" where one lagging study holds up the entire filing. Enable parallel IND strategies across multiple geographies.

#### Discovery Questions
1. "How many preclinical studies are in your current IND-enabling package, and how do you track progress across internal labs and CROs?"
2. "Have you ever had an IND filing delayed because a single preclinical study was behind schedule — and what was the cost of that delay in terms of competitive positioning?"
3. "How do you manage protocol deviations and GLP compliance documentation across multiple CROs?"
4. "What's your process for determining the critical path through preclinical to IND, and how far in advance do you identify bottlenecks?"

#### Industry Context
IND-enabling studies are governed by Good Laboratory Practice (GLP) regulations (21 CFR Part 58). The IND application to the FDA includes three main sections: Pharmacology/Toxicology, CMC, and Clinical Protocol. The "Pre-IND meeting" with FDA is a critical milestone. CRO management is a major pain point — pharma companies work with specialized CROs like Covance (Labcorp Drug Development), Charles River, Inotiv. Study timelines vary enormously: a 28-day repeat-dose tox study takes ~6 months end-to-end including reporting, while a 2-year carcinogenicity study takes ~3 years.

---

#### 🔧 VIBE PROMPT

> **"Build This Live" Prompt:**
>
> "Build a Preclinical Study Tracker board for IND-enabling packages. Groups by study category: Toxicology, Safety Pharmacology, Genotoxicity, ADME/PK, Reproductive Toxicology. Columns: Study Name (text), Study Type (dropdown: Single-Dose Tox, 28-Day Repeat-Dose Tox, 13-Week Repeat-Dose Tox, 26-Week Repeat-Dose Tox, Carcinogenicity, CV Safety Pharm, Respiratory Safety Pharm, CNS Safety Pharm, Ames Genotox, In Vitro Micronucleus, In Vivo Micronucleus, Rat PK, Dog PK, ADME, Fertility, Embryo-Fetal Development, Pre/Postnatal Development), Species (dropdown: Rat, Mouse, Dog, NHP, Rabbit, In Vitro), CRO (dropdown: Covance, Charles River, Inotiv, Internal), Study Director (people), GLP Compliant (status: Yes, No, Exempt), Protocol Status (status: Draft, Finalized, Amended), In-Life Start Date (date), In-Life End Date (date), Draft Report Due (date), Final Report Due (date), Study Status (status: Planning, Protocol Finalization, In-Life, Pathology/Analysis, Draft Report, QA Review, Final Report), Protocol Deviations (numbers), IND Section (dropdown: Section 5.3 Pharm/Tox, Section 5.2 CMC-Related, Section 5.4 Clinical), Notes (long text). Add a Timeline view showing all studies Gantt-charted from In-Life Start to Final Report Due. Add a Dashboard with: (1) chart of study count by Status, (2) battery showing % of studies at Final Report, (3) chart of deviations by CRO, (4) critical path timeline for IND filing. Add automations: when Final Report Due is within 14 days and Study Status is not QA Review or Final Report, notify Study Director and Head of Nonclinical with 'IND Study at Risk'; when Study Status changes to Final Report, check if all items in all groups are at Final Report — if yes, notify VP R&D with 'IND Package Complete — Ready for Filing'."

---

#### 🤖 AGENT BLUEPRINT — monday AI Agents *(coming soon)*

**Agent Name:** PreClinIQ
**Agent Purpose:** Track preclinical study milestones across CROs, predict IND-filing readiness, and flag GLP compliance risks.

**Triggers:**
- Weekly scan every Monday at 8:00 AM
- When Study Status changes on any item
- When Protocol Deviations count increases
- When a CRO misses a Draft Report Due date
- 90 days before target IND filing date (escalation mode)

**Actions:**
- Calculate IND-readiness score based on percentage of studies at Final Report stage
- When a CRO misses a milestone, auto-generate impact analysis on IND timeline and suggest mitigation (accelerate pathology, parallel QA review)
- Flag GLP compliance concerns when Protocol Deviations exceed 3 for any study
- Generate CRO performance scorecards (on-time delivery, deviation rates, report quality)
- At 90 days before IND target, switch to daily monitoring and generate countdown dashboard
- Recommend optimal study sequencing for future programs based on historical CRO performance data

**Data Required:**
- CRO contract milestones and deliverable schedules
- Historical study timelines by type and CRO
- GLP audit findings database

**Autonomy Level:** Human-in-the-Loop
Monitoring and alerting are autonomous. Any recommendation that involves CRO escalation, protocol amendments, or IND timeline changes requires Study Director and VP Nonclinical approval.

**Example Interaction:**
> PreClinIQ detects that Charles River has missed the Draft Report Due date for the 13-week repeat-dose toxicology study in dogs by 12 days. This study is on the critical path for IND filing. The agent calculates: "At current delay, IND filing will slip from April 15 to May 8. However, if Charles River delivers draft by March 1, and QA review is expedited to 10 days (vs. standard 15), filing can be recovered to April 20 — 5-day slip only. Recommend: (1) Escalate to Charles River Study Director and request expedited pathology peer review, (2) Pre-schedule QA reviewer for March 1 draft receipt, (3) Begin drafting IND Pharm/Tox summary using preliminary data to parallelize." The agent sends notifications to the Head of Nonclinical, the CRO Relationship Manager, and the Regulatory Affairs Lead.

---

### Use Case 4: R&D Collaboration Hub — Cross-Functional Program Teams

**Relevance:** High
**Value Driver:** Replace or Radically Augment Headcount

#### The Pain
Drug development programs involve 10-20 functional representatives (medicinal chemistry, biology, DMPK, toxicology, clinical, regulatory, CMC, commercial, medical affairs) who meet weekly in "program team meetings." Meeting prep, action item tracking, decision logging, and cross-functional handoffs are managed through a chaotic mix of meeting minutes in Word, action items in email, and decisions buried in PowerPoint. Program managers spend 60-70% of their time on coordination rather than strategic program leadership. When team members change (which happens frequently), institutional knowledge is lost.

#### The Solution
monday.com as the program team collaboration workspace. Each program gets a workspace with connected boards: Decision Log (decisions with rationale, date, attendees, status), Action Items (owner, due date, status, linked decision), Meeting Agenda/Minutes (date, topics, pre-reads, attendees), Risk Register (risk, likelihood, impact, mitigation, owner), and the master Program Timeline. Connected boards link actions to decisions to risks. Automations create recurring meeting items, track overdue actions, and escalate unresolved risks.

#### The Outcome
Reduce program manager coordination overhead by 40-50%, freeing them for strategic activities. New team members onboard in days instead of weeks by reviewing the decision log and risk register. Eliminate the "we already discussed this" problem that costs programs 2-3 months per year in rework.

#### Discovery Questions
1. "How many cross-functional program teams are active in your R&D organization, and what does a typical program manager's week look like in terms of coordination vs. strategic work?"
2. "When a key team member rotates off a program, how long does it take the replacement to get up to speed — and what knowledge is typically lost?"
3. "How do you currently log program decisions and their rationale — could you reconstruct why a specific formulation or dosing regimen was chosen two years ago?"
4. "What percentage of program team meeting time is spent reviewing action items from previous meetings versus advancing the program forward?"
5. "How do regulatory, clinical, and CMC teams stay synchronized on program timelines — do they share a common view?"

#### Industry Context
The "program team" or "development team" (DT) structure is universal in pharma R&D. It's typically led by a Program Director or Global Program Leader (GPL), with functional representatives from each discipline. The Joint Development Committee (JDC) or Portfolio Committee provides governance. SEs should know that decision traceability is not just nice-to-have — it's a regulatory expectation. FDA and EMA inspectors ask "why did you choose this dose?" and expect documented rationale.

---

#### 🔧 VIBE PROMPT

> **"Build This Live" Prompt:**
>
> "Build a Drug Development Program Team Hub workspace with 4 connected boards. Board 1 — Decision Log: columns: Decision Title (text), Decision Date (date), Category (dropdown: Formulation, Dosing, Study Design, Regulatory Strategy, Manufacturing, Commercial, Safety), Decision (long text), Rationale (long text), Attendees (people), Status (status: Proposed, Approved, Revisited, Superseded), Risk Impact (status: Low, Medium, High), Connected Actions (connect to Board 2). Board 2 — Action Items: columns: Action (text), Owner (people), Due Date (date), Status (status: Open, In Progress, Blocked, Complete, Cancelled), Priority (status: Critical, High, Standard), Source Meeting (connect to Board 3), Linked Decision (connect to Board 1), Notes (long text). Board 3 — Meeting Minutes: columns: Meeting Date (date), Meeting Type (dropdown: Weekly Program Team, Ad Hoc, Governance Review, Regulatory Strategy, Safety Review), Attendees (people), Agenda Items (long text), Key Decisions (long text), Pre-Read Documents (files), Actions Generated (connect to Board 2). Board 4 — Risk Register: columns: Risk Description (text), Category (dropdown: Scientific, Regulatory, Manufacturing, Clinical, Commercial, Safety), Likelihood (status: Low, Medium, High), Impact (status: Low, Medium, High, Critical), Mitigation Plan (long text), Owner (people), Status (status: Open, Mitigating, Accepted, Closed), Review Date (date). Add automations on Board 2: when Due Date is today and Status is not Complete, notify Owner; when Status is Blocked for >3 days, notify Owner's manager. Add automation on Board 3: every Monday at 9 AM, create new item with today's date, Meeting Type = Weekly Program Team, populate Attendees from previous meeting."

---

#### 🤖 AGENT BLUEPRINT — monday AI Agents *(coming soon)*

**Agent Name:** ProgramPulse
**Agent Purpose:** Automate program team coordination, maintain institutional memory, and surface cross-functional risks before they become crises.

**Triggers:**
- 24 hours before each scheduled program team meeting
- When an Action Item status changes to Blocked
- When a Risk Register item's Likelihood changes to High
- When a new Decision is logged with Risk Impact = High
- Monthly comprehensive program health review

**Actions:**
- Pre-meeting: auto-generate agenda by pulling overdue actions, open risks, and pending decisions; attach to meeting item
- Post-meeting: parse meeting notes and auto-create Action Items with owners and due dates
- When an action is Blocked, analyze dependencies and suggest resolution path based on historical patterns
- Generate "Institutional Memory Brief" for new team members — summarizing key decisions, rationale, and active risks
- Monthly: produce program health scorecard comparing timeline adherence, action item completion rate, and risk resolution velocity
- Flag when decisions in one program may conflict with decisions in related programs (e.g., shared manufacturing platform)

**Data Required:**
- Team member roster and role assignments
- Calendar integration for meeting scheduling
- Historical decision and action item data across programs

**Autonomy Level:** Human-in-the-Loop
Agenda generation and action item creation are autonomous (with human review). Decision logging always requires human confirmation. Cross-program conflict flagging surfaces recommendations for human evaluation.

**Example Interaction:**
> ProgramPulse prepares for tomorrow's weekly program team meeting for the VERTEX-204 program (Phase II, type 2 diabetes). It generates: "📋 Agenda for Jan 28 Program Team Meeting: (1) 3 overdue actions — Dr. Chen's biomarker assay validation (due Jan 20), CMC team's stability protocol amendment (due Jan 22), and regulatory's FDA Type B meeting request draft (due Jan 25). (2) Risk escalation: R-007 'API supply single-source risk' likelihood upgraded to High after supplier audit findings. Mitigation plan review needed. (3) Pending decision: D-045 'Dose selection for Phase IIb' — proposed by Clinical, awaiting DMPK and Tox input. (4) New business: Commercial team requests early market sizing discussion." The agenda is attached to the meeting item and sent to all program team members 24 hours before the meeting.

---

### Use Case 5: Scientific Literature & Competitive Intelligence Monitoring

**Relevance:** Medium-High
**Value Driver:** Replace or Radically Augment Headcount

#### The Pain
R&D teams must continuously monitor scientific publications, patent filings, conference presentations (ASCO, AACR, ADA, AAN), and competitor pipeline updates. Medical affairs and competitive intelligence analysts spend 20-30 hours/week scanning PubMed, ClinicalTrials.gov, patent databases, and conference abstracts. Critical information — a competitor's Phase III readout, a new safety signal in the same drug class, a breakthrough mechanism paper — often reaches program teams days or weeks late, compromising strategic decisions.

#### The Solution
monday.com board for competitive intelligence and literature tracking. Items represent intelligence events with columns: Source (dropdown: PubMed, ClinicalTrials.gov, Patent Filing, Conference Abstract, Press Release, FDA/EMA Communication), Competitor (dropdown), Therapeutic Area (dropdown), Relevance (status: Critical, High, Medium, Low), Date Published (date), Summary (long text), Impact Assessment (long text), Affected Programs (connect boards), Assigned Analyst (people), Action Required (status: None, Brief Team, Update Strategy, Urgent Review), Link (link). Dashboards show intelligence heatmaps by TA and competitor.

#### The Outcome
Reduce competitive intelligence cycle time from weeks to days. Ensure no critical publication or competitor event is missed. Free 15-20 hours/week of analyst time from scanning toward strategic analysis. Enable faster "sense and respond" when competitors report Phase III data or safety signals.

#### Discovery Questions
1. "How does your R&D organization currently stay on top of competitor pipeline developments and scientific publications relevant to your therapeutic areas?"
2. "Can you recall a time when a competitor's clinical readout or a key publication was identified too late to adjust your development strategy?"
3. "How many people are dedicated to competitive intelligence and literature monitoring, and what percentage of their time is scanning vs. strategic synthesis?"
4. "When a relevant paper is published in a major journal, what's the current process for it to reach the relevant program team and trigger a strategic discussion?"

#### Industry Context
Pharma R&D competitive intelligence is a specialized discipline. Key conferences (ASCO for oncology, ADA for diabetes, AAN for neurology, ACR for rheumatology) are where Phase III data breaks. ClinicalTrials.gov amendments (protocol changes, endpoint modifications) can signal competitor strategy shifts. Patent cliffs and BPCIA biosimilar filings directly affect commercial viability. The "competitive landscape slide" is a fixture of every portfolio review.

---

#### 🔧 VIBE PROMPT

> **"Build This Live" Prompt:**
>
> "Build a Competitive Intelligence Tracker board. Groups: by Therapeutic Area (Oncology, Immunology, Neuroscience, Metabolic, Rare Disease). Columns: Intelligence Item (text), Source Type (dropdown: PubMed Publication, ClinicalTrials.gov Update, Patent Filing, Conference Abstract, Press Release, FDA Communication, EMA Communication, Analyst Report), Competitor (dropdown: list top 15 pharma companies — Pfizer, Roche, Novartis, Merck, J&J, AbbVie, BMS, Lilly, AstraZeneca, Sanofi, GSK, Amgen, Gilead, Regeneron, Novo Nordisk), Relevance (status: Critical, High, Medium, Low — Critical = red, Low = light gray), Date Published (date), Date Identified (date), Summary (long text), Strategic Impact (long text), Affected Internal Programs (connect boards — link to Portfolio Tracker), Analyst (people), Action Required (status: No Action, Brief Program Team, Strategy Review Needed, Urgent Leadership Review), Source URL (link), Conference (dropdown: ASCO, AACR, ADA, AAN, ACR, EASL, ASH, ESMO, JPM, Other, N/A). Add a Kanban view grouped by Action Required. Add a Dashboard with: (1) chart of intelligence items by Competitor over time, (2) chart by Source Type, (3) chart of Critical + High items by TA, (4) table widget showing items with Action Required = Urgent Leadership Review. Add automations: when Relevance is set to Critical, immediately notify Head of R&D Strategy and relevant TA Head; when Action Required changes to Brief Program Team, create an action item on the linked program's Action Items board."

---

#### 🤖 AGENT BLUEPRINT — monday AI Agents *(coming soon)*

**Agent Name:** SciScan
**Agent Purpose:** Autonomously monitor scientific literature, competitor activity, and regulatory communications, then classify and route intelligence to relevant program teams.

**Triggers:**
- Scheduled scan every 6 hours across configured data sources
- When a new item is manually added (for analyst-sourced intelligence)
- Conference season mode: hourly scans during ASCO, ADA, AAN, ESMO week
- When a competitor's ClinicalTrials.gov entry shows a status change (e.g., "Recruiting" → "Active, not recruiting" = enrollment complete)

**Actions:**
- Scan PubMed for new publications matching therapeutic area keywords and competitor compound names
- Classify relevance using therapeutic area, mechanism of action overlap, and development stage proximity
- Auto-generate 3-sentence summary and preliminary impact assessment for each item
- Route Critical items directly to TA Head and affected Program Directors
- Compile weekly intelligence digest by therapeutic area, ranked by relevance
- During conference weeks, produce daily "Conference Flash" reports with abstracts relevant to internal programs

**Data Required:**
- PubMed API access with configured search terms per TA
- ClinicalTrials.gov API for competitor study monitoring
- Internal program list with compound names, targets, indications, and phases
- Conference abstract databases (ASCO, ESMO, etc.)

**Autonomy Level:** Fully Autonomous (for scanning and classification) / Human-in-the-Loop (for strategic impact assessments)
SciScan scans, classifies, and routes without human intervention. Strategic impact assessments on Critical items are generated as drafts for analyst review before distribution to leadership.

**Example Interaction:**
> SciScan detects a new publication in the New England Journal of Medicine: "Phase III Results of CompetitorX's PD-L1/VEGF Bispecific Antibody in First-Line NSCLC." The agent classifies it as Critical for the Oncology TA, identifies overlap with internal programs HORIZON-301 (PD-1 monotherapy, Phase III NSCLC) and BEACON-102 (PD-1/LAG-3 bispecific, Phase I). It generates: "⚠️ CRITICAL: CompetitorX reports ORR 48.2% vs. 36.1% for pembrolizumab in 1L NSCLC (p<0.001), mPFS 11.2 vs. 7.4 months. Implications: (1) Sets new efficacy bar for 1L NSCLC — HORIZON-301's PD-1 monotherapy approach faces differentiation challenge, (2) BEACON-102's LAG-3 mechanism is differentiated but must demonstrate comparable or superior efficacy in PD-L1 high subgroup, (3) Recommend urgent competitive strategy review for both programs." Notifications sent to VP Oncology, HORIZON-301 Program Director, and BEACON-102 Program Director.

---

### Use Case 6: Lab Operations & Experiment Tracking

**Relevance:** Medium-High
**Value Driver:** Scale Impact Without Overhead

#### The Pain
Discovery and early development labs run hundreds of experiments weekly — compound synthesis, biological assays, formulation studies, analytical method development. Scientists use electronic lab notebooks (ELNs) for raw data but lack a lightweight operational layer for tracking experiment queues, instrument scheduling, reagent inventory, and cross-team requests. Instrument downtime, reagent stockouts, and uncoordinated priorities between chemistry and biology teams cause 15-20% throughput loss in most labs.

#### The Solution
monday.com as the lab operations layer (complementing, not replacing, ELNs). Boards for: Experiment Queue (experiment name, requestor, technique, instrument, priority, status, target date), Instrument Schedule (instrument, maintenance date, next calibration, availability status), Reagent & Consumables Tracker (item, vendor, lot number, quantity, reorder point, expiry date), and Cross-Team Requests (requesting team, receiving team, request type, samples needed, timeline, status). Automations alert when reagent quantities hit reorder points and when instrument maintenance is due.

#### The Outcome
Increase lab throughput by 15-25% through better resource coordination. Eliminate experiment delays due to reagent stockouts or instrument scheduling conflicts. Give lab heads visibility into team workload and capacity for resource allocation decisions.

#### Discovery Questions
1. "How do your lab teams currently manage experiment prioritization and instrument scheduling — is there a shared queue or does each scientist manage their own?"
2. "What's the estimated throughput loss from instrument downtime, reagent stockouts, or scheduling conflicts in a typical month?"
3. "When biology needs compounds from chemistry or vice versa, how are those cross-team requests tracked and prioritized?"
4. "How do lab heads allocate team capacity across competing program requests — is that data-driven or intuition-based?"

#### Industry Context
Pharma R&D labs are high-cost environments ($500-2,000/sqft annually). Common instruments: HPLC/UPLC (chromatography), mass spectrometers, NMR, flow cytometers, plate readers, automated liquid handlers. Scientists' time is the scarcest resource — fully loaded cost of a PhD scientist is $300-500K/year. ELNs (IDBS E-WorkBook, Dotmatics, Benchling) capture scientific data; what's missing is the operational/coordination layer.

---

#### 🔧 VIBE PROMPT

> **"Build This Live" Prompt:**
>
> "Build a Lab Operations Hub workspace with 3 boards. Board 1 — Experiment Queue: columns: Experiment Name (text), Requestor (people), Program (dropdown: list 8-10 programs), Technique (dropdown: HPLC, Mass Spec, NMR, Flow Cytometry, ELISA, Cell-Based Assay, Synthesis, Formulation, Stability, Analytical Method Dev), Instrument Required (dropdown: HPLC-01, HPLC-02, LCMS-01, NMR-500, FlowCyt-01, PlateReader-01, AutoSynth-01), Priority (status: Urgent, High, Standard, Low), Status (status: Queued, Scheduled, In Progress, Analysis, Complete, Failed), Target Start Date (date), Target Completion (date), Actual Completion (date), ELN Reference (text), Results Summary (long text). Board 2 — Instrument Schedule: columns: Instrument Name (text), Instrument Type (dropdown: HPLC, LCMS, NMR, Flow Cytometer, Plate Reader, Liquid Handler), Location (dropdown: Lab A, Lab B, Lab C, Analytical Suite), Status (status: Available, In Use, Maintenance, Calibration Due, Down), Next Calibration Date (date), Last Maintenance (date), Responsible Scientist (people). Board 3 — Reagent Tracker: columns: Reagent Name (text), Catalog Number (text), Vendor (dropdown: Sigma-Aldrich, Fisher, VWR, Thermo, Corning, Internal), Lot Number (text), Quantity On Hand (numbers), Unit (dropdown: mg, g, kg, mL, L, units), Reorder Point (numbers), Expiry Date (date), Storage Condition (dropdown: RT, 4°C, -20°C, -80°C), Location (text). Add automations: on Board 3, when Quantity On Hand drops below Reorder Point, notify Lab Manager with 'Reorder Needed: {Reagent Name}'; on Board 2, when Next Calibration Date is within 7 days, notify Responsible Scientist; on Board 1, when Priority = Urgent and Status = Queued for >24 hours, notify Lab Head."

---

#### 🤖 AGENT BLUEPRINT — monday AI Agents *(coming soon)*

**Agent Name:** LabOps
**Agent Purpose:** Optimize lab resource utilization, prevent operational bottlenecks, and automate routine lab management tasks.

**Triggers:**
- Daily at 7:00 AM: scan experiment queue and instrument schedule
- When Reagent Tracker Quantity On Hand is updated
- When an instrument status changes to Down
- When a new Urgent experiment is added to the queue

**Actions:**
- Optimize daily experiment scheduling based on instrument availability, reagent stock, and scientist workload
- When an instrument goes Down, identify all affected queued experiments and suggest rescheduling to alternative instruments or dates
- Predict reagent consumption based on queued experiments and proactively flag stockout risks before they hit reorder point
- Generate weekly lab utilization report: instrument uptime %, experiment throughput, average queue-to-completion time
- When cross-team requests are pending >48 hours, escalate to both team leads
- Recommend experiment batching opportunities (e.g., "3 HPLC runs for different programs could share a mobile phase prep — saves 2 hours")

**Data Required:**
- Instrument booking calendars
- Historical experiment run times by technique
- Reagent consumption rates per experiment type
- Scientist availability/calendar

**Autonomy Level:** Fully Autonomous (for monitoring and scheduling suggestions) / Human-in-the-Loop (for actual schedule changes)
LabOps suggests optimal schedules but scientists confirm. Reagent reorder alerts are autonomous. Instrument rescheduling recommendations require Lab Head approval.

**Example Interaction:**
> LabOps detects that LCMS-01 is going down for scheduled maintenance on Wednesday, but there are 4 mass spec experiments queued for Wednesday-Thursday across 3 programs (2 High priority, 2 Standard). The agent checks: LCMS-02 is available Wednesday PM and all day Thursday. It proposes: "LCMS-01 maintenance conflict: Recommend moving Dr. Patel's PK sample analysis (High) to LCMS-02 Wednesday 1-5 PM, and Dr. Kim's metabolite ID (High) to LCMS-02 Thursday 8 AM-12 PM. The 2 Standard priority runs can shift to Friday when LCMS-01 returns. This preserves both High priority program timelines." Lab Head reviews and approves with one click.

---

### Use Case 7: Regulatory Intelligence & Health Authority Interaction Tracker

**Relevance:** Medium
**Value Driver:** Consolidate Tech Stack with AI

#### The Pain
Regulatory affairs teams interact with 5-15 health authorities globally per program — Pre-IND meetings (FDA), Scientific Advice (EMA), pre-submission consultations (PMDA). Each interaction generates commitments, questions, and guidance that must be tracked, addressed, and referenced in subsequent submissions. Teams use fragmented systems — email, shared drives, Veeva Vault — to manage meeting minutes, commitment logs, and response documents. When FDA asks in Year 3 "did you follow the guidance we gave in Year 1?", teams scramble to locate and verify compliance with prior commitments.

#### The Solution
monday.com as the health authority interaction management system. Each interaction is an item with columns: Health Authority (dropdown), Meeting Type (dropdown: Pre-IND, Type A, Type B, Type C, Scientific Advice, Pre-Submission, Breakthrough Therapy, Fast Track, Orphan Designation), Date (date), Program (connect boards), Commitments Made (long text), Questions Asked (long text), FDA/EMA Response (long text), Compliance Status (status: All Met, In Progress, At Risk, Overdue), Next Interaction (date), Regulatory Lead (people), Meeting Minutes (files). Connected "Commitments" sub-board tracks individual commitments with owners and due dates.

#### The Outcome
100% traceability of health authority commitments across program lifecycle. Eliminate audit findings related to unfulfilled regulatory commitments. Reduce meeting prep time by 60% when prior interaction history is instantly accessible. Enable faster regulatory strategy decisions based on precedent analysis.

#### Discovery Questions
1. "How many health authority interactions has your regulatory team conducted in the past 12 months, and how do you track commitments from those meetings?"
2. "During an FDA inspection or advisory committee, how quickly can you retrieve the complete interaction history for a specific program?"
3. "Have you ever discovered that a commitment from a prior health authority meeting was not addressed in a subsequent submission?"
4. "How do your global regulatory teams share learnings — does EMA Scientific Advice inform your FDA strategy, or do regions operate independently?"

#### Industry Context
Health authority interactions are strategic negotiations. FDA has structured meeting types (Type A: urgent, 30-day response; Type B: standard, 60-day; Type C: less critical, 75-day). EMA Scientific Advice is the European equivalent. Breakthrough Therapy Designation (BTD), Fast Track, Accelerated Approval, and Priority Review are FDA expedited programs that require specific interactions. The concept of "regulatory commitment" is quasi-contractual — failing to honor commitments can result in Complete Response Letters (CRLs).

---

#### 🔧 VIBE PROMPT

> **"Build This Live" Prompt:**
>
> "Build a Health Authority Interaction Tracker board. Groups by Health Authority: FDA, EMA, PMDA, NMPA, Health Canada, Other. Columns: Meeting Title (text), Meeting Type (dropdown: Pre-IND, Type A, Type B, Type C, End-of-Phase-2, Pre-NDA, Scientific Advice, Protocol Assistance, Pre-Submission Conference, Breakthrough Therapy Meeting, Orphan Designation, REMS Discussion, Pediatric Study Plan), Meeting Date (date), Program (connect boards — link to Portfolio Tracker), Therapeutic Area (dropdown), Regulatory Lead (people), Meeting Minutes Document (files), Key Questions Submitted (long text), Agency Response Summary (long text), Commitments Made (long text), Commitment Status (status: All Fulfilled, In Progress, At Risk, Overdue), Next Interaction Planned (date), Expedited Designation (dropdown: Breakthrough Therapy, Fast Track, Accelerated Approval, Priority Review, PRIME, Orphan, None), Notes (long text). Add a sub-items structure where each commitment is a sub-item with: Commitment Description (text), Owner (people), Due Date (date), Status (status: Open, In Progress, Complete, Waived), Evidence Document (files). Add a Kanban view grouped by Commitment Status. Add automations: when a sub-item Due Date is within 30 days and Status is Open, notify Owner and Regulatory Lead; when all sub-items for a meeting are Complete, update parent Commitment Status to All Fulfilled."

---

#### 🤖 AGENT BLUEPRINT — monday AI Agents *(coming soon)*

**Agent Name:** RegMemory
**Agent Purpose:** Maintain complete institutional memory of health authority interactions and ensure no regulatory commitment falls through the cracks.

**Triggers:**
- Weekly scan of all open commitments every Monday
- 60 days before any Next Interaction Planned date
- When a new interaction item is created
- When a commitment sub-item's Due Date is within 14 days and Status is not Complete
- Quarterly comprehensive compliance review

**Actions:**
- Pre-meeting: compile complete interaction history for the relevant program and health authority, highlighting all prior commitments and their status
- Post-meeting: parse meeting minutes to identify new commitments and auto-create sub-items with suggested owners and due dates
- Generate "Commitment Compliance Report" for regulatory leadership showing fulfillment rates by program, HA, and team
- Cross-reference commitments across health authorities to identify conflicts or opportunities for harmonized approaches
- When preparing for an FDA Advisory Committee, compile all prior FDA interactions into a briefing document
- Flag when a commitment is At Risk and suggest remediation based on similar past situations

**Data Required:**
- Historical meeting minutes and commitment databases
- Regulatory submission timelines
- Team member assignments and capacity

**Autonomy Level:** Escalation-Based
Commitment tracking and reminders are autonomous. Pre-meeting briefing compilation is autonomous. Commitment identification from meeting minutes is generated as drafts for Regulatory Lead review. Any commitment status escalation to At Risk triggers notification to VP Regulatory Affairs.

**Example Interaction:**
> RegMemory prepares for a Pre-NDA meeting with FDA for the APEX-305 program. It compiles: "Complete FDA Interaction History for APEX-305: 7 interactions over 4 years. Pre-IND (March 2022): 4 commitments — all fulfilled. Type B (Sept 2022): 3 commitments — all fulfilled. End-of-Phase-2 (June 2024): 5 commitments — 4 fulfilled, 1 IN PROGRESS (Commitment EOP2-5: 'Submit updated carcinogenicity data with NDA' — carcinogenicity study final report due Feb 28, currently in QA Review). Breakthrough Therapy Meeting (Jan 2025): 2 commitments — both fulfilled. ⚠️ ATTENTION: EOP2-5 is on the critical path. If carcinogenicity report is not finalized by Feb 28, this commitment will be unfulfilled at time of NDA filing. Recommend discussing timeline with FDA during Pre-NDA meeting as a contingency." This briefing is attached to the Pre-NDA meeting agenda item.

---

## Industry Terminology

| Term | Definition |
|------|-----------|
| IND | Investigational New Drug application — required before human clinical trials begin |
| NDA/BLA | New Drug Application / Biologics License Application — submitted for marketing approval |
| CTD | Common Technical Document — standardized format for regulatory submissions (5 modules) |
| eCTD | Electronic Common Technical Document — the electronic submission format |
| GLP | Good Laboratory Practice — quality standards for preclinical studies |
| GMP | Good Manufacturing Practice — quality standards for drug manufacturing |
| GCP | Good Clinical Practice — quality standards for clinical trials |
| PTRS | Probability of Technical and Regulatory Success — used in portfolio valuation |
| CRO | Contract Research Organization — outsourced research partner |
| CTMS | Clinical Trial Management System — software for managing clinical studies |
| ELN | Electronic Lab Notebook — digital record of experiments |
| LIMS | Laboratory Information Management System |
| eTMF | Electronic Trial Master File — regulatory-required clinical trial documentation |
| DMPK | Drug Metabolism and Pharmacokinetics |
| CMC | Chemistry, Manufacturing, and Controls — drug substance/product quality section |
| CSR | Clinical Study Report — detailed report of a clinical trial |
| IB | Investigator's Brochure — document provided to clinical investigators |
| PDUFA | Prescription Drug User Fee Act — sets FDA review timelines/dates |
| CRL | Complete Response Letter — FDA's formal communication that an application is not approved |
| TA | Therapeutic Area — disease-focused organizational unit |

## Typical Stakeholder Roles

| Role | Responsibility | Influence |
|------|---------------|-----------|
| VP/SVP R&D | Overall R&D strategy and portfolio decisions | Decision-maker |
| Global Program Leader (GPL) | Leads cross-functional development team for a specific program | Decision-maker (program level) |
| Head of Nonclinical/Preclinical | Oversees all preclinical studies and IND-enabling packages | Decision-maker (preclinical) |
| Head of Clinical Operations | Manages clinical trial execution across all programs | Decision-maker (clinical ops) |
| VP Regulatory Affairs | Leads regulatory strategy and health authority interactions | Decision-maker |
| Head of CMC/Pharmaceutical Sciences | Drug substance and product manufacturing | Decision-maker (CMC) |
| Program Manager | Coordinates cross-functional program team activities | Influencer (key operational role) |
| Director, Competitive Intelligence | Monitors competitive landscape and external developments | Influencer |
| Lab Head / Group Leader | Manages discovery or development lab operations | Influencer (lab level) |
| Scientist / Senior Scientist | Executes experiments, generates data | User |
| Regulatory Affairs Associate | Prepares and tracks submission documents | User |
| Clinical Research Associate (CRA) | Monitors clinical trial sites | User |

## Adjacent Departments

| Department | Connection | Opportunity |
|-----------|-----------|-------------|
| Clinical Operations | Executes trials designed by R&D; shares program timelines | Clinical trial management, site activation tracking |
| Manufacturing / CMC | Process development and scale-up depend on R&D formulation decisions | Tech transfer tracking, batch record management |
| Medical Affairs | Translates R&D data into medical communications and KOL engagement | Publication tracker, MSL activity management |
| Commercial / Marketing | Launch planning depends on R&D timelines and data readiness | Pre-launch planning board, market access tracker |
| Quality Assurance | Audits GLP/GMP/GCP compliance across R&D activities | Audit tracker, CAPA management |
| Finance | Manages R&D budgets, program-level P&L, and capital allocation | Program budget tracker, resource planning |
| IT | Manages scientific computing, lab informatics, and validated systems | System validation tracker, IT project management |
| Legal / IP | Patent strategy directly tied to R&D compound development | Patent lifecycle tracker, freedom-to-operate analysis |

## Competitive Landscape

| Tool | Positioning | Displacement Opportunity |
|------|------------|------------------------|
| Veeva Vault R&D Suite | Industry-standard for regulated document management (eTMF, RIM, Quality) | monday.com as operational/collaboration layer alongside Veeva (complement, not replace for regulated docs) |
| Planisware | Enterprise PPM for pharma R&D portfolio management | monday.com offers faster deployment, better UX, and AI capabilities at lower cost; ideal for teams frustrated with Planisware complexity |
| Smartsheet | Used by some R&D teams for project tracking and timelines | monday.com provides richer automation, better dashboards, and the AI platform vision |
| Microsoft Project / Planner | Basic project management, often used in R&D for timelines | monday.com is more collaborative, visual, and scalable with superior integrations |
| Benchling | R&D informatics platform (ELN + LIMS for biotech) | monday.com complements Benchling as the operational/program management layer |
| Dotmatics (was IDBS) | ELN and scientific data management | Similar complement strategy — monday.com for ops, Dotmatics for scientific data |
| IDBS E-WorkBook | Electronic lab notebook for pharma R&D | Complement; monday.com handles the operational layer ELNs don't cover |
| Jira | Used by some R&D informatics/computational teams | monday.com Dev product offers similar functionality with better cross-functional visibility |

## Objection Handling

| Objection | Response |
|-----------|----------|
| "We're a validated environment — we can't use non-validated tools for regulated work" | "monday.com is positioned as the operational and collaboration layer, not the system of record for regulated documents. Your GxP data stays in Veeva/validated systems. monday.com handles the coordination, tracking, and decision-making workflows that currently live in unvalidated spreadsheets and email — which is actually a bigger compliance risk." |
| "We already have Veeva Vault for everything" | "Veeva excels at regulated document management, but your program teams, lab operations, and portfolio management are running on spreadsheets and PowerPoint. That's the gap monday.com fills — the 80% of R&D work that isn't regulated document storage but still needs structure and visibility." |
| "Our IT won't approve another tool — we have too many already" | "That's exactly why consolidation is a value driver. monday.com can replace 5-10 point solutions (Smartsheet, Trello, shared spreadsheets, MS Project) with one platform. The AI capabilities mean you're not just consolidating — you're upgrading to a platform where AI does the coordination work." |
| "Pharma R&D is too complex for a work management tool" | "The complexity is exactly why you need a flexible platform rather than rigid tools. Your programs are unique — different therapeutic areas, different regulatory paths, different team structures. monday.com adapts to how you actually work instead of forcing you into a template designed for software development." |
| "We need 21 CFR Part 11 compliance" | "For audit trails and electronic signatures on regulated records, you'll continue using validated systems. monday.com serves the operational layer — the same layer currently running in Excel, which has zero audit trail. We're actually improving your compliance posture for non-GxP workflows." |

## Proof Points
*(To be populated with customer references)*
- [Pharma companies using monday.com for R&D program management]
- [Biotech companies using monday.com for clinical operations coordination]
- [Life sciences organizations that consolidated project management tools onto monday.com]

---

*Generated: February 19, 2026 | Version: 2.0 (with Vibe Prompts + Agent Blueprints)*
